United States allows Regeneron processing

The treatment that was used to cure Donald Trump last October is officially licensed in the United States, Saturday, by the United States Drug Administration (FDA).

This change occurs after administration of REGEN-COV2, a combination of two laboratory-made antibodies, has been shown to reduces Covid-19-related hospitalizations or emergency room visits in patients with secondary diseases or “comorbidities”.

According to the FDA, authorization of this type of treatment could “allow patients to avoid hospitalization” and to lighten the load that the coronavirus is putting pressure on the American healthcare system.

The president of Regeneron, Leonard Schleifer, assured that this decision was “an important step in the fight against Covid-19, because high-risk patients in the United States will have access to promising therapy early in your infection“.

At the beginning of October, Donald Trump had received this cocktail of “monoclonal” antibodies developed by the American company Regeneron. The president widely praised the quality of his treatment after his recovery.

More effective treatment at the beginning of the infection.

These antibodies mimic what the immune system does after infection with the coronavirus, going block virus tip allowing it to adhere and penetrate human cells.

He is regarded as most effective during the initial phase of infection, when the antibodies still have a chance to control the invader, and not during the second phase of Covid-19, when the danger is no longer the virus itself, but the overreaction of the immune system that attacks the lungs and other organs.

Regeneron’s antibody therapy is the second synthetic antibody therapy to receive “Emergency Use Authorization” (US) from the FDA. A similar therapy developed by the American company Eli Lilly had already obtained this status on November 9.

Regeneron received more than $ 450 million from the US government. for his efforts to develop drugs against Covid-19.

The writing recommends you

read more

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button